专题：CNS Lymphoma Diagnosis and Treatment

This cluster of papers focuses on the diagnosis, treatment, and management of primary central nervous system lymphoma (PCNSL). It covers various aspects such as prognostic scoring systems, chemotherapy and radiotherapy regimens, use of methotrexate and rituximab therapy, genetic features, neurological masquerade syndromes, and cognitive functions in PCNSL patients.
最新文献
High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial

article Full Text OpenAlex

Diagnosis of primary CNS lymphoma through molecular and immune biomarkers in cerebrospinal fluid (PRICELUS): a multicentre, prospective, cohort study

article Full Text OpenAlex

Tafasitamab plus lenalidomide and R-CHOP versus R-CHOP for first-line treatment of patients with high-risk diffuse large B-cell lymphoma (frontMIND): a global, phase 3, randomised, double-blind, placebo-controlled trial

article Full Text OpenAlex

Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in TP53 -Mutated Diffuse Large B-Cell Lymphoma

article Full Text OpenAlex

Tucidinostat Plus R-CHOP vs R-CHOP in MYC/BCL2 Double-Expressor Diffuse Large B-Cell Lymphoma

article Full Text OpenAlex

Immunodeficiency-associated primary CNS lymphomas: an International Primary CNS Lymphoma Collaborative Group study

article Full Text OpenAlex

Current treatment algorithm: diffuse large B cell lymphoma

article Full Text OpenAlex

Burkitt Lymphoma—A Guide to Biological Features, Diagnosis and Differential Diagnosis

article Full Text OpenAlex

Prognostic impact of TP53 mutations in diffuse large B-cell lymphoma

article Full Text OpenAlex

2026 Update on the Management of Diffuse Large B‐Cell Lymphoma

article Full Text OpenAlex

近5年高被引文献
Primary central nervous system lymphoma

review Full Text OpenAlex 253 FWCI12.0215

Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma

article Full Text OpenAlex 228 FWCI26.3128

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

article Full Text OpenAlex 181 FWCI47.1419

Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study

article Full Text OpenAlex 175 FWCI18.3016

Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial

article Full Text OpenAlex 174 FWCI16.0488

Epidemiology and etiology of diffuse large B-cell lymphoma

article Full Text OpenAlex 172 FWCI28.3091

European Association of Neuro-Oncology (EANO) guidelines for treatment of primary central nervous system lymphoma (PCNSL)

article Full Text OpenAlex 163 FWCI14.0944

Proposed New Dynamic Prognostic Index for Diffuse Large B-Cell Lymphoma: International Metabolic Prognostic Index

article Full Text OpenAlex 159 FWCI18.351

Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial

article Full Text OpenAlex 152 FWCI11.1496

Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments

article Full Text OpenAlex 149 FWCI18.1541